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Abstract
DNA diagnostics are useful but are hampered by difﬁcult ethical issues. Moreover, it cannot provide
enough information on the environmental factors that are important for pathogenesis of certain diseases.
However, this is not a problem for RNA diagnostics, which evaluate the expression of the gene in question.
We here report a novel RNA diagnostics tool that can be employed with peripheral blood mononuclear
cells (PBMCs). To establish this tool, we identiﬁed 290 genes that are highly expressed in normal
PBMCs but not in TIG-1, a normal human ﬁbroblast cell. These genes were entitled PREP after predomi-
nantly expressed in PBMC and included 50 uncharacterized genes. We then conducted PREP gene-
focused microarray analysis on PBMCs from seven cases of Churg–Strauss syndrome (CSS), which is a
small-vessel necrotizing vasculitis. We found that PREP135 (coactosin-like protein), PREP77 (prosaposin),
PREP191 (cathepsin D), PREP234 (c-fgr), and PREP136 (lysozyme) were very highly up-regulated in all
seven CSS patients. Another 28 genes were also up-regulated, albeit more moderately, and three were
down-regulated in all CSS patients. The nature of these up- and down-regulated genes suggest that the
immune systems of the patients are activated in response to invading microorganisms. These observations
indicate that focused microarray analysis of PBMCs may be a practical, useful, and low-cost bedside diag-
nostics tool.
focused microarray; RNA diagnosis; PMBC; allergic granulomatosis angiitis; Churg–Strauss
syndrome
1. Introduction
The advent of array technology and the subsequent
development of high-density oligonucleotide arrays
1
have been enormously helpful in improving our
understanding of the genome-wide transcriptional
proﬁles of many biological systems in both basic and
applied research.
2 Array technology has also been
extremely useful for discovering and developing diag-
nostic gene markers for disease subcategories, disease
prognosis, and treatment outcome; this has paved the
way for effective pharmaceutical drug discovery, the
development of novel strategies for molecular (DNA,
RNA) diagnostics, and the design of personalized
drug regimens.
2
Oligonucleotide microarrays, which were initially
designed to analyze genome-wide gene expression
levels, have turned out to be particularly useful in
DNA diagnosticsastheycanbe usedformanydifferent
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3 With regard to the latter appli-
cations, such DNA diagnostics have greatly improved
our understanding of and ability to detect the causa-
tive mutations of various diseases. However, this tech-
nologyis hampered bymajorethicaland privacyissues
since the genome sequence of a person carries
unchangeable private information whose discovery
can affect the life of not only that person, but also to
some extent their family members. The need to
protect patient privacy upon DNA diagnostics testing
and the practical problems this constitutes also
imposes extra costs on the testing procedure.
Moreover, many kinds of diseases are caused not only
by the DNA polymorphism, but also by environmental
status. These environmental factors can be reﬂected in
the RNA status, but DNA diagnostics usually cannot
provide enough information on the environments.
Thus, the activity of the disease can be detected by
RNA or protein level but not by DNA level.
These problems are not faced by RNA diagnostics, in
whichthegenome-widemRNA levelsaremonitoredby
oligonucleotide(orcDNA)microarrays.Ethicalissuesof
the nature described above do not apply here because
the information obtained from RNA diagnostics does
not necessarily relate to the DNA sequence. Instead,
this technology monitors the dynamic changes in
gene activities, namely, the increased or decreased
transcriptional (mRNA) levels in the samples provided
by the individual. The transcriptional levels would
vary in the same individual depending on the health
of the individual. In this sense, DNA diagnostics is a
static test of the genome, whereas RNA diagnostics is
a dynamic test of the genome.
However, it is not possible to monitor all 44 000
kinds of mRNA species that are transcribed from the
human genome for many samples at the same time.
A novel way to circumvent this problem is to
develop a ‘focused array’ in which a limited number
of mRNAs are tested in a low-density array. In the
present study, we developed a focused oligonucleotide
(or cDNA) array for use with patient peripheral blood
mononuclear cells (PBMCs). For this, we selected the
genes that are predominantly expressed in normal
PBMCs, as determined by stepwise subtractive hybrid-
ization
4 and by genome-wide cDNA microarray analy-
sis. From the 290 ‘PBMC-focused’ genes we identiﬁed,
we can prepare the PBMC-focused cDNA array. We
examined the expression levels of these PREP genes
to analyze the PBMC RNAs obtained from patients
suffering the autoimmune disease Churg–Strauss
syndrome (CSS), which is an alternative name of aller-
gic granulomatosis angiitis, because the autoimmune
response of CSS patients is expected to disturb the
expression levels of immune-related genes in PBMC.
Indeed, we identiﬁed several genes whose expressions
are markedly up- or down-regulated in all CSS
patients tested. These observations suggest that this
low-cost RNA diagnostics test is useful, practical, and
can be used at the bedside.
2. Patients, Materials and methods
2.1. Human subjects: patients and healthy controls
Blood was obtained from eight healthy volunteers
(four males and four females; aged 25–49 years)
for the cDNA library preparation. Blood was also
obtained from seven cases of CSS patients whose pro-
ﬁles are shown in Supplementary Table S1 and 18
healthy controls (six males and 11 females; aged
25–86 years) for focused microarray analysis. CSS
patients were diagnosed according to the diagnostic
criteria of the American College of Rheumatology.
5
This study was reviewed and approved by the Internal
Review Board of the Research Institute for Microbial
Diseases, Osaka University. In accordance with the
requirements of the Board, a written informed
consent was obtained from each participant before
venous blood samples were obtained. Serum samples
were consecutively obtained regardless of the patient’s
symptom, active, or inactive phase.
2.2. Preparation of RNA
The RNA of the PBMCs obtained from healthy
volunteers was prepared as described previously.
6
Brieﬂy, heparinized venous blood (10 mL) was
mixed with an equal volume of 2% dextran/saline sol-
ution and incubated at room temperature for 30 min
to precipitate the red blood cells. Total RNA was
extracted from the PBMC pellet by adding guani-
dine–thiocyanate solution and the samples were
used for cDNA library preparation and subtractive
hybridization.
7 Total RNA was also prepared by acid
guanidinium–phenol–chloroform extraction for the
DNA microarray, northern blot, and RT–PCR analyses.
In some experiments, total RNA was synthesized using
Ribo Max kit (Promega, Madison, WI) from the PBMC
cDNA library. Total RNA or mRNA from human ﬁbro-
blast TIG-1 cells was prepared as described pre-
viously.
7 ExTaq DNA polymerase for RT–PCR was
purchased from TaKaRa Co. Ltd. (Otsu, Japan). Probe
labeling and detection for northern blots were per-
formed by using the Gene Images Random-Prime
Labelling and Detection System (GE Healthcare Bio-
Sciences Corp., Piscataway, NJ).
2.3. Preparation of the subtracted cDNA library and
stepwise subtraction
Poly(A)
þ RNA was puriﬁed from total RNA by
oligo(dT) cellulose chromatography. A cDNA library
104 RNA Diagnosis Using PBMC [Vol. 15,with eight million independent clones was con-
structed from the PBMC mRNAs by using the linker-
primer method and the pAP3neo vector as described
previously.
7 The poly(A)
þ RNAs from exponentially
growing TIG-1 cells that had been incubated with
10% serum in tissue culture plates were also puriﬁed
and biotinylated by using photobiotin. After convert-
ing the cDNA library to a single-stranded form by
transfection with an f1 helper phage, we hybridized
it with the biotinylated mRNAs and subtracted it by
biotin–avidin interactions.
7 The unhybridized clones
were converted to the double-stranded form and
used to transform competent Escherichia coli cells.
This generated a ﬁrst-stage subtracted cDNA library
of 11 million independent clones.
We then prepared plasmid DNA from  800 ran-
domly selected cDNA clones and numbered and
digested an aliquot of each plasmid DNA with SmaI
and NotI restriction enzymes to prepare 10 sheets of
Southern blots, each of which included 80 clones
arranged in order. We then puriﬁed the cDNA
inserts of clones 1–20 on 1% agarose gels by digest-
ing them with EcoRI and NotI; these inserts were
labeled with ﬂuorescent dye and then used as
probes for northern analysis with PBMC and TIG-1
RNAs to determine which clones contained PREP
genes (data not shown). The DNA sequences of the
PREP clones from the 50 end of the cDNA inserts
were determined by the dideoxy-chain termination
reaction using an automatic DNA sequencer (Licor
4000L; Lincoln, NE). After these analyses, we selected
the next 20 unhybridized clones on the Southern blot
(from 21 onwards) for the next round of cDNA insert
preparation,ﬂuorescentlabeling,andnorthernanalysis.
Thisprocedurewasrepeateduntilweﬁnishedtestingall
800 unhybridized clones. The PREP genes identiﬁed in
the preceding step were then converted to RNA, bio-
tinylated with photobiotin, and used to subtract the
ﬁrst-stage subtracted cDNA library. The second-stage
subtractedcDNAlibrary wasthenanalyzedasdescribed
above and subtracted again. This process was repeated
three times as described previously.
4
After the clones whose transcription was conspicu-
ously up-regulated in PBMCs as compared with TIG-
1 cells were sequenced, the DNA sequences were
used to search the EST database by using the BLAST
algorithm (http://www.ncbi.nlm.nih.gov/BLAST/).
2.4. Human cDNA microarray analysis for
identiﬁcation of PREP genes
The total RNAs (500 ng) from the normal human
PBMCs were pooled, as were the TIG-1 cell RNAs,
after which both pools were reverse-transcribed by
using oligo-dT primers containing the T7 RNA poly-
merase promoter sequence. The cDNAs were then
subjected to in vitro transcription using T7 RNA poly-
merase to label the complementary RNAs (cRNAs)
with cyanine 3 (Cy3)-CTP or cyanine 5 (Cy5)-CTP
(Amersham Pharmacia Biotech, Piscataway, NJ). The
Cy-labeled cRNAs from the normal human PBMCs
(1 mg) were then mixed with the same amount of
reverse color Cy-labeled TIG-1 cell-derived cRNAs.
Hybridizations, rinsing, scanning, and gene analysis on
the Agilent’s all human cDNA microarray (Hu44K)
were conducted according to the manufacturer’s pro-
tocol (G2940BA; Agilent Technologies, Inc., Palo Alto,
CA). Fluorophore reversal (dye swap) duplicates were
used in two-color DNA microarray experiments. The
399 genes that showed the highest level of up- or
down-regulation were selected and subjected to RT–
PCR analysis using the normal human PBMC and
TIG-1 RNAs (Fig. 1) with relevant oligonucleotide
primers (Supplementary Table S2). Of these, 122
genes were identiﬁed as PREP genes, 33 of which
were already identiﬁed as PREP genes by stepwise
subtraction.
4
2.5. Individual microarray analysis on CSS patients
The quality of the RNA samples obtained from
PBMCs of each CSS patient was examined by using
the RNA 6000 Nano LabChip Kit (p/n 5065-4476)
on the Agilent 2100 Bioanalyzer. To conduct the indi-
vidual cDNA microarray (Hu44K) analysis on CSS
patients and normal volunteers, we generated ﬂuores-
cently labeled cRNA by in vitro transcription with
T7 RNA polymerase in the presence of Cy5-CTP
or Cy3-CTP using a Low RNA Input Fluorescent
Linear Ampliﬁcation Kit (Agilent Technologies, Inc.)
as described above. The Cy5-labled cRNA of each
patient was then mixed with the Cy3-labled cRNA of
normal volunteers to probe the cDNA microarray.
PREP gene expression analysis was then conducted
by using the Gene Spring software 7.3.1 (Agilent
Technologies, Inc.) by setting appropriate parameters
to select 33 or 3 PREP genes whose expressions are
up-regulated (.1.2-fold change) or down-regulated
(,1.0-fold change) in all seven CSS patients as com-
pared with healthy volunteers. We also conducted
similar analysis to select nine conspicuously up-regu-
lated PREP genes (.2.0-fold change).
3. Results
3.1. Isolation of putative PBMC-speciﬁc genes
To isolate putative human PBMC-speciﬁc genes, we
ﬁrst prepared mRNAs from the PBMCs of healthy vol-
unteers and generated a human PBMC cDNA library
with 80 million independent clones by using the
linker-primer method described previously.
7 We also
prepared mRNAs from exponentially growing normal
No. 2] T. Tougan et al. 105human ﬁbroblast TIG-1 cells, which are control cells
that express non-PBMC transcripts. These mRNAs
were biotinylated with photobiotin
7 and used to sub-
tract the PBMC cDNA library as described previously
4
to remove the housekeeping and non-PBMC-speciﬁc
genes. Brieﬂy, after converting the PBMC cDNA
library to a single-stranded form by transfection
with f1 helper phage, we hybridized it with the
Figure 1. Identiﬁcation of PREP genes. Individual PREP cDNA clones were subjected to northern blot or RT–PCR analysis to compare their
gene expression levels in the PBMCs of healthy volunteers (right lanes, denoted as P) and human ﬁbroblast TIG-1 cells (left lanes,
denoted as T). The names of the PREP genes are shown in Table 1. The RT–PCR data for GAPDH and the northern blot data for
b-actin are also shown as loading controls. The annealing temperature and ampliﬁcation cycles used in the RT–PCRs are denoted to
the left of each image by a–h: a, 508C and 35 cycles, b, 508C and 30 cycles, c, 558C and 35 cycles, d, 558C and 40 cycles, e, 558C
and 45 cycles, f, 558C and 30 cycles, and g, 508C and 40 cycles, respectively. The northern blots are denoted as n.
106 RNA Diagnosis Using PBMC [Vol. 15,biotinylated TIG-1 mRNAs and subtracted it by
biotin–avidin interactions. The unhybridized clones
were converted to the double-stranded form, which
was then used to transform competent E. coli cells,
thereby generating a subtracted cDNA library.
To analyze this subtracted cDNA library, we pre-
pared plasmid DNA from several hundred randomly
selected and numbered cDNA clones. An aliquot of
each plasmid DNA was then digested with EcoRI
and NotI and their cDNA inserts were puriﬁed on
1% agarose gels and ﬂuorescently labeled. These
probes were then used in northern analysis to identify
those genes whose transcript levels were much higher
in PBMCs than in TIG-1 cells, namely, those genes that
Figure 1. Continued
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genes were named PREP after predominantly
expressed in PBMC. As shown in Fig. 1, each northern
sheet only included two lanes, one each for the RNAs
extracted from PBMCs and TIG-1. The DNA sequences
of these candidate PREP genes were determined from
the 50 end of the cDNA inserts by the dideoxy-chain
termination reaction and were used to search the
EST database by employing the BLAST algorithm
(http://www.ncbi.nlm.nih.gov/BLAST/). For those
candidate PREP genes whose northern blot signals
were weak or undetectable, we examined whether
these candidate genes were indeed up-regulated by
RT–PCR using oligonucleotide primers based on the
DNA sequences of these genes (Supplementary
Table S2) (Fig. 1). These procedures were repeated
until almost all subtracted cDNAs were tested, as
described previously.
4 The end result was the isolation
of 197 PREP genes.
To reduce the possibility of missing important
PBMC-speciﬁc pathogenic genes by the stepwise
subtraction method, we also performed in parallel a
genome-wide cDNA microarray analysis by using
Agilent’s Hu44K array with the same pooled RNA
samples obtained from the PBMCs and TIG-1. The
399 genes that showed the greatest up-regulation in
PBMCs compared with TIG-1 were then tested by
RT–PCR. This resulted in the identiﬁcation of 126
PREP genes, 33 of which were the same as those
obtained by the stepwise subtraction analysis. The
candidate PREP genes were tested by northern and/
or RT–PCR analyses to conﬁrm their PBMC-specifc
expression (Fig. 1). We did not test those genes
that showed lower up-regulation in PBMCs than the
399 genes because the efﬁciency of detecting a
PREP was conspicuously lower in the top 151–400
microarray genes than in the top 1–150 genes.
Thus, it appears that while the stepwise subtraction
method failed to identify 93 PREP genes, the DNA
microarray analysis failed to detect 164 PREP genes.
This disparity is mainly due to the differently sized
drivers or probes used for hybridization; cDNA sub-
traction uses kilobase-order biotinylated mRNA as
the driver for subtraction, while DNA microarrays
are probed by 60-base oligonucleotides. These data
together indicate that we identiﬁed 290 PREP genes
(Supplementary Table S3).
3.2. Characterization of the unknown PREP genes
Of the 290 PREP genes that we identiﬁed, PREP1–
PREP50 are uncharacterized genes. Homology and
motif search of the gene products (Prep1–Prep50
proteins) using the Motif Scan algorithm (http://
myhits.isb-sib.ch/cgi-bin/motif_scan) revealed the
following notable motifs in PREP1–PREP11 (Fig. 2),
which may suggest their putative physiological func-
tions. The other uncharacterized PREP genes did not
have any notable motifs.
PREP1 encodes an RNA-binding protein because
it harbors three RNA recognition motifs.
8 PREP2
encodes a protein that harbors a V-set Ig-like
domain that is responsible for binding to sialic acid.
9
A specialized subgroup of the Ig superfamily, called
sialic acid-binding immunoglobulin-like lectins
(Siglecs), can recognize sialylated glycoconjugates
and play a role in cell–cell recognition and intracellu-
lar signaling. At least 11 related genes have been
identiﬁed in the human genome, all of which
encode type 1 membrane proteins that carry an N-
terminal sialic acid-binding V-set Ig domain and
varying numbers of C2-set Ig domains.
9 Thus, Prep2
may be a Siglec-type protein. Prep3 protein belongs
to the large calcineurin-like phosphoesterase super-
family. Members of this superfamily include the poly-
merase-associated B-subunits and all carry an active
site harboring two divalent metal ions for catalysis.
10
This suggests that Prep3 protein may participate in
cell growth by regulating DNA replication. PREP4
Figure 2. Schematic depiction of the uncharacterized gene
products Prep1-Prep11. Numbers indicate the amino acids of
the protein. RRM, RNA recognition motif; GEF, Guanine
nucleotide exchange factor; PH, pleckstrin homology; LisH, LIS1
(lissencephaly) homology; bZIP, basic region/leucine zipper;
Sir2, sirtuin 2; FAD, ﬂavin adenine dinucleotide.
108 RNA Diagnosis Using PBMC [Vol. 15,encodes a novel member of the paxillin family pro-
teins that bear the RhoGEF and PH domains.
11
Paxillin is a multi-domain adaptor that recruits
associated proteins to focal adhesions, where it
plays a pivotal role in transducing cell signaling,
thereby eliciting changes in cell migration and gene
expression.
12 Given that the RhoGEF and PH
domains both are also found in these cell signaling
molecules, Prep4 protein appears to function in the
signal transduction of growth signals. PREP5 encodes
a protein with a LisH (LIS1 homology) motif, which
is found in many signaling proteins of the WD-40
family and is believed to help regulate microtubule
dynamics by mediating dimerization or binding to
cytoplasmic dynein heavy chain.
13 Prep6 protein is
homologous to laminin A, which is one of the 15
laminin isoforms that are the major component of
basement membranes.
14 PREP7 encodes a basic-
leucine zipper (bZip) transcription factor
15 with a
DNA-binding motif called AT-hook.
16 PREP8 encodes
a protein that is weakly homologous to Sir2, an
NAD-dependent deacetylase that links metabolism
with longevity in yeast, ﬂies, and worms.
17 Prep9
protein harbors a region that is weakly homologous
to extensin, a hydroxyproline-rich cell wall structural
glycoprotein of higher plants.
18 The N-terminal
region of Prep10 protein bears a domain that has
homology to the adenovirus hexon-associated
protein IX.
19 Prep11 protein carries in its C-terminus
a domain with homology to the ﬂavin adenine dinu-
cleotide (FAD)-binding domain of siderophore-inter-
acting protein which may be involved in iron
chelation and iron utilization.
20
3.3. Expression pattern of PREP1–PREP11 and
proto-oncogene PREP genes in PBMCs
To determine whether the uncharacterized PREP1–
PREP11 genes are expressed in particular human
blood cells, we performed RT–PCR on multiple
tissue cDNA (MTC) panels from Clontech (Palo Alto,
CA). As shown in Fig. 3, PREP3, PREP4, and PREP6
mRNAs were only detected in resting CD14þ cells
(monocytes; M), whereas PREP1 mRNAs were predo-
minantly found in monocytes but were also faintly
expressed in resting CD19þ cells (B cells). In addition,
PREP11 showed a strong signal in monocytes and B
cells and a weak signal in T-suppressor/cytotoxic
cells and activated CD4þ T cells. PREP2 was strongly
detected in monocytes, T-helper/inducer, and B
cells, and weakly in T-suppressor/cytotoxic and acti-
vated CD4þ cells. PREP7 was strongly expressed in
all mononuclear cells (B cells, T cells, and monocytes),
weakly expressed in activated CD8þ T cells, and
faintly expressed in activated CD4 þ , CD19 þ , and
mononuclear cells. PREP10 was detected strongly in
all resting mononuclear cells, but only faintly in the
other cell types examined. The other PREP genes
were ubiquitously expressed at almost equal levels in
all cell types examined and indeed could serve as a
loading control like GAPDH.
Unexpectedly, we found six proto-oncogenes were
PREP genes, namely, c-ets,c - src,c - yes,c - fgr,c - fos, and
c-vav. We initially asked whether the augmented
expression of these proto-oncogenes is due to infec-
tion-induced T-cell or macrophage stimulation in
one of the PBMC donors. To test this, we examined
the expression of these proto-oncogenes by RT–PCR
on the MTC panel described above, since the sample
RNAs used to generate the panel is not the same as
our RNAs (Fig. 4). To our surprise, we found all cell
types examined strongly expressed c-ets,c - src, and
c-yes. All mononuclear cells (B cells, T cells, and mono-
cytes) and activated CD4þ and CD19þ cells, but not
activated CD8þ and mononuclear cells, also
expressed c-vav. In contrast, c-fgr was only detected
in T-suppressor/cytotoxic cells, while c-fos was only
detected in resting T-suppressor/cytotoxic cells, B
cells, and mononuclear cells. Thus, the expression of
these proto-oncogenes is a commonly observed
phenomenon.
Figure 3. Determination by RT–PCR of the human blood cells that
express PREP1–PREP11. RT–PCR was performed using a multiple
tissue cDNA panel for human blood fractions (MTC, Clontech).
GAPDH was also ampliﬁed as a loading control. PCR
ampliﬁcations involved 40 cycles at 558C except as indicated
to the right of the panels: 35 cycles at 558C (#) or 35 cycles
at 588C ($). Lane 1, mononuclear cells (B cells, T cells, and
monocytes). Lane 2, resting CD8þ cells (T-suppressor/
cytotoxic cells). Lane 3, resting CD4þ cells (T-helper/inducer).
Lane 4, resting CD14þ cells (monocytes). Lane 5, resting
CD19þ cells (B cells). Lane 6, activated CD19þ cells. Lane 7,
activated mononuclear cells (aMNC). Lane 8, activated CD4þ
cells. Lane 9, activated CD8þ cells.
No. 2] T. Tougan et al. 1093.4. Focused PREP analysis of CSS PBMCs
We next examined whether the PREP genes can
serve in a focused array that can be used to diag-
nostically. For this purpose, we used the array to
determine if CSS patients can be characterized by a
particular PREP mRNA expression pattern. CSS is a
rare autoimmune disease (ca. 2.4 per million),
namely, a small-vessel necrotizing vasculitis that is
typically characterized by asthma, lung inﬁltrates,
extravascular necrotizing granulomas, and hypereosi-
nophilia.
21 This disease was chosen because diagnos-
tic gene markers for this disease have not yet been
reported. Moreover, it is likely that the symptoms of
CSS patients will be reﬂected in abnormal gene
expressions in their PBMCs. Indeed, we found with
the aid of expression proﬁling analysis (GeneSpring)
that, compared with normal volunteers, 33 PREP
genes are consistently up-regulated in the PBMCs of
all seven cases of CSS patients tested (Fig. 5A, upper-
most panel). Of these, PREP135, PREP77, PREP191,
PREP234, and PREP136, which are highlighted by
larger arrows in Fig. 5A, showed the most conspicuous
up-regulation in all CSS patients (.2.5-fold change).
PREP135 encodes the coactosin-like protein (CLP),
which is a small, evolutionarily conserved F-actin-
binding protein that can also bind to 5-lipoxygenase
(5LO) and regulate its activity.
22 PREP77 encodes pro-
saposin, the precursor of the sphingolipid activator
proteins (saposin A, B, C, and D) that are required
for the enzymatic hydrolysis of sphingolipids by
speciﬁc lysosomal hydrolases.
23 PREP191, which
encodes a lysosomal aspartyl peptidase cathepsin D
(CTSD), is known to be involved in prosaposin
Figure 4. Expression proﬁles of the indicated proto-oncogenes in
human blood fractions. RT–PCR was performed using the
multiple tissue cDNA panel (MTC, Clontech). GAPDH was also
ampliﬁed as a loading control. PCR ampliﬁcations involved 35
cycles at 558C for all samples. Lane 1, mononuclear cells (B, T
cells and monocytes). Lane 2, resting CD8þ cells (T-
suppressor/cytotoxic cells). Lane 3, resting CD4þ cells (T-
helper/inducer). Lane 4, resting CD14þ cells (monocytes).
Lane 5, resting CD19þ cells (B cells). Lane 6, activated
CD19þ cells. Lane 7, activated mononuclear cells (aMNC).
Lane 8, activated CD4þ cells. Lane 9, activated CD8þ cells.
Figure 5. Expression proﬁles of PREP genes in CSS patient PBMCs.
Agilent’s whole human genome DNA microarray was
employed for this analysis. (A) Presentation of mosaic tiles for
the 33 and 3 PREP genes whose expressions are up-regulated
(.1.2-fold change) or down-regulated (,1.0-fold change) in
all seven CSS patients as compared with healthy volunteers.
The gene names are indicated on the right of the panels. The
PREP genes were selected by a ﬁlter and their expressions in all
seven cases of CSS patients were grouped together by using
GeneSpring software 7.3 (Agilent Technologies, Inc.). In other
words, their raw expression values were normalized according
to the manufacturer’s instructions by conducting a ratio
calculation of the two channels. This was followed by a per-
gene normalization to ensure all ratios for each gene were
normalized to 1. The nine conspicuously up-regulated PREP
genes (.2.0-fold change) are denoted by arrows; the ﬁve large
arrows signify more enhanced up-regulation (.2.5-fold
change). Tile colors indicate the mean relative transcript level;
green corresponds to a log10 ratio of 0.01 (down-regulation),
red corresponds to a log10 ratio of 100 (up-regulation), and
yellow indicates unchanged (bottom-most panel) when CSS
and normal PBMCs are compared (bottom-most panel). (B)
Graphical presentation of the nine CSS-up-regulated and three
CSS-down-regulated PREP genes (denoted by arrows in Fig.
5A). Mean values were plotted for the genes that showed a
signiﬁcant (P , 0.05) difference in expression. The ordinate
scale indicates relative log ratio values.
110 RNA Diagnosis Using PBMC [Vol. 15,proteolysis.
24 Thus, the enhanced expression of
PREP77 and PREP191 suggests sphingolipid levels
are increased in CSS. This is consistent with the
pivotal role sphingolipids are known to play as proin-
ﬂammatory factors.
25 Thus, sphingolipids and related
enzymes may not only be diagnostic marker for CSS,
they may also be novel therapeutic targets in CSS
(see Discussion).
PREP234 encodes Gardner–Rasheed feline sarcoma
viral (v-fgr) oncogene homolog (c-fgr: FGR), which
is known to play an important role in lipopolysacchar-
ide (LPS)-induced macrophage activation.
26 Indeed,
Fgr-deﬁcient mice fail to develop lung eosinophilia
in response to repeated challenge with aerosolized
ovalbumin (OVA)
27. Src-family tyrosine kinases are
required to support the accumulation of polymor-
phonuclear leukocytes (PMN) along with adherent
platelets at the site of vascular injury.
28 PREP136
encodeslysozyme,whichisoneofthegenesresponsible
for autosomal dominant hereditary amyloidosis.
29
Indeed, there are several case reports of amyloidosis
associated with CSS that occurs together with a
destructive inﬂammatory or granulomatous reaction
to amyloid.
30 Several case reports have also described
granulomatous angiitis in patients with sporadic,
amyloid beta peptide (Abeta)-related cerebral
amyloid angiopathy and Abeta-related angiitis with
development of amyloid-associated inﬂammation.
31
There are also four other less conspicuously CSS-
up-regulated PREP genes (2.0–2.5-fold change). Of
these, PREP226 encodes a receptor (membrane)-
type variant of the protein tyrosine phosphatase
(PTPepsilonM) family protein that negatively regu-
lates insulin receptor (IR) signaling by dephosphory-
lating IR, thereby suppressing the phosphorylation of
IR downstream enzymes such as Akt, extracellular
regulated kinase (ERK), and glycogen synthase
kinase 3 (GSK3).
32 Notably, the cytosolic isoform of
PTPepsilon (PTPepsilonC) selectively inhibits inter-
leukin-6 (IL-6)- and IL-10-induced Janus kinases
(JAK)-signal transducer and activator of transcription
3 (STAT3) signaling in blood cells.
33
Another of the four less conspicuously up-regulated
PREP genes, PREP113, encodes platelet factor 4 (PF4;
CXC chemokine ligand 4), which is a speciﬁc marker
for megakaryocyte cells and that induces the differen-
tiation of monocytes into macrophages during the
inﬂammatory process.
34 PREP286 encodes lysoso-
mal-associated multi-spanning membrane protein-5
(LAPTM5). While the function of LAPTM5 is
unknown, it may participate in host defense in collab-
oration with other lysosome-related genes (PREP77,
PREP191, and PREP136) in the blood cells of CSS
patients. These results suggest that the regulation
of cell signaling in blood cells from CSS patients is
abnormal. The last of the four less conspicuously up-
regulated PREP genes is PREP203, which encodes the
spliceosomal protein thioredoxin-like 4B (TXNL4B).
However, its physiological signiﬁcance in the patho-
genesis of CSS remains unclear.
We also identiﬁed three PREP genes that, compared
with normal volunteers, are down-regulated in the
PBMCs of all seven CSS patients (Fig. 5A, middle panel).
PREP76 encodes nicastrin;
35 its down-regulation may
disturb the phagocytic response of macrophages to
inﬂammatory cytokines since gamma-secretase cata-
lyzes the intramembrane cleavage of its protein sub-
strates and targets phagocytosis-related proteins of
macrophages.
36 PREP114 encodes selectin P ligand
(SELPLG), which stimulates T lymphocytes, and plays
a critical role in the tethering of these cells to acti-
vated platelets or endothelia expressing P-selectin.
37
PREP283 encodes sperm-associated antigen 9 (SPAG9),
which has also been identiﬁed as a serum target
of the autoantibody produced in systemic sclerosis
(SSc).
38 Thus, the reduced expression of these three
genes could also serve as diagnostic markers of CSS.
Unfortunately, we could not correlate the expression
levels of these genes to the proﬁles of tested CSS
patients (Supplementary Table S1).
3.5. Expression pattern of CSS-up-regulated PREP genes
in PBMCs
To examine whether these 12 CSS-up- or -down-
regulated PREP genes are expressed in particular
human blood cells, we performed RT–PCR on MTC
panels (Fig. 6). PREP76, PREP135, and PREP203 were
expressed by nearly all cells, and were the only
genes that were expressed by activated CD19þ and
activated CD8þ cells. Most of the 12 PREP genes
were expressed by resting CD14þ cells (monocyte;
M) and T-helper/inducer (T-h/i) cells, albeit with
different expression levels. All genes except PREP283
were expressed by T-suppressor/cytotoxic (T-s/c)
cells. PREP76, PREP113, PREP114, PREP135, and
PREP203 were expressed at varying expression levels
by activated mononuclear cells (aMNC). All genes
except PREP114, PREP135, and PREP283 were
expressed by B cells, albeit comparatively weakly.
Thus, many of the CSS-up-regulated or -down-
regulated PREP genes are expressed by T cells or mono-
cytes. Unfortunately, we could not perform the same
analysis on CSS patients because of the low numbers
of PBMCs available.
4. Discussion
4.1. Isolation of genes that are predominantly
expressed in human PBMCs
Here we show for the ﬁrst time (to our knowledge)
that RNA diagnostics can be performed by using a
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methods have the advantage over DNA diagnostics
in that ethical problems concerning the genetic infor-
mation of individuals are avoided. To select the PBMC-
speciﬁc genes for use in RNA diagnostics, we utilized a
technique that we developed previously, namely, step-
wise subtraction.
4 In this technique, all genes
expressed by a particular cell, tissue, or whole organ-
ism are used to generate a cDNA library. This library
is then systematically subtracted in a stepwise
manner by using the biotinylated mRNAs from a
control population to isolate essentially all those
genes that are up-regulated relative to the control
population expression proﬁle. This technique has
proven to be useful for isolating the protein-coding
genes that are speciﬁcally expressed during cancer
metastasis, meiosis, and spermatogenesis, and in
patients with autoimmune diseases.
4,39–41 It has
also been used to identify putative non-coding RNAs
that cannot be identiﬁed by microarray screening.
42
By using this technique along with high-density oligo-
nucleotide microarray analysis, we identiﬁed 290
PREP genes that are predominantly expressed in
human PBMCs as compared with ﬁbroblast (TIG-1)
cells (Fig. 1 and Table 1). These genes could be used
to generate a PBMC-speciﬁc focused array that could
be used to characterize the abnormal expression pro-
ﬁles in the PBMCs of patients with a particular disease.
The abnormal proﬁles could then serve as a diagnostic
tool for other patients presenting with this disease.
The 290 PREP genes we identiﬁed include 50
uncharacterized genes, 11 of which possess notable
amino acid motifs (Fig. 2). Two of these, PREP1 and
PREP6, were almostexclusivelyexpressedinmonocytes
(Fig. 6). Of the 240 PREP genes that have been charac-
terized previously, 11, eight, eight, seven, six, ﬁve, ﬁve,
nine, and 36 are HLA genes, CD antigen genes, ribo-
somal protein genes, interferon (IFN)-related genes,
S100 calcium-binding protein-related genes, inter-
leukin (IL)-related genes, platelet-related genes,
signal transduction-related genes, and immunity-
related genes, respectively (Supplementary Table S4).
We did not identify any other immunity-related
genes as PREP genes by these techniques, probably
because their expression levels are lower than the
PREP genes.
4.2. PBMC-speciﬁc array analysis with CSS patients
To explore the usefulness of the PBMC-speciﬁc
focused array analysis in RNA diagnostics, we tested
the PBMCs of seven cases of CSS patients.
21 The
precise pathogenetic mechanisms of CSS remain
elusive, in part because the rarity of this disease. We
found that compared with normal volunteers, 22
PREP genes were up-regulated by .1.5-fold in the
PBMCs of all seven CSS patients (Fig. 5). Of these,
PREP135, PREP77, PREP191, PREP234, PREP136,
PREP203, and PREP113 were the most conspicuously
up-regulated in CSS patients. How these genes
contribute to the pathogenesis of CSS is suggested by
the known functions of their products, as follows.
PREP77 (prosaposin) and PREP135 (CLP) may indicate
the enhanced immune responses that cause vascular
inﬂammation; PREP203 (TXNL4B) and PREP234
(c-fgr) may reﬂect the augmented intracellular signal-
ing that occurs after an infection causes inﬂammation;
and the increased expression of the lysosome-related
genes PREP77, PREP136, PREP191, and PREP286 may
indicate the mounting of an effective defense against
invading microorganisms by the lysosomes in blood
cells. Thus, our PREP gene-focused analysis of CSS
patientshashelpedtoidentifygenesthatmaybeputa-
tive diagnostic and/or therapeutic targets.
There are few molecular tools that can be used to
aid the diagnosis of CSS. The main tool that is com-
monly employed is the detection of antineutrophil
cytoplasmic autoantibodies (ANCA), which can be
Figure 6. Expression of CSS-up-regulated or -down-regulated PREP
genes by various human blood cells. RT–PCR was performed
with the MTC. The GAPDH expression proﬁle served as a
loading control. All PCR ampliﬁcations involved 35 cycles at
558C. We could not detect an ampliﬁed band for PREP119
even though we tested three different primer sets
(Supplementary Table S1). Lane 1, mononuclear cells (B, T
cells and monocytes). Lane 2, resting CD8þ cells (T-
suppressor/cytotoxic cells). Lane 3, resting CD4þ cells (T-
helper/inducer). Lane 4, resting CD14þ cells (monocytes).
Lane 5, resting CD19þ cells (B cells). Lane 6, activated
CD19þ cells. Lane 7, activated mononuclear cells (aMNC).
Lane 8, activated CD4þ cells. Lane 9, activated CD8þ cells.
112 RNA Diagnosis Using PBMC [Vol. 15,detected by an immunoﬂuorescent assay (IFA) on
ethanol-ﬁxed neutrophils. ANCA are associated with
systemic necrotizing vasculitis and glomerulonephritis
diseases such as CSS, Wegener’s granulomatosis (WG),
and microscopic polyarteritis (MPA).
43 Two different
ANCA immunostaining patterns are observed, namely,
a diffuse cytoplasmic staining pattern (c-ANCA) that
recognizes proteinase 3, and a perinuclear/nuclear
pattern(p-ANCA)thatcommonlyrecognizesmyeloper-
oxidase (MPO), which is a neutrophil granule protein
that helps generate oxygen radicals and is associated
with the antimicrobial properties of neutrophils. The
c-ANCA pattern is most frequently observed in WG
patients, whereas the p-ANCA pattern is detected in
CSS and MPA patients.
44 Notably, ANCAs against
alternative antigens such as cathepsin G, which is a
major protease released by activated neutrophils, are
also occasionally observed.
Since antibodies against cathepsin D (PREP191),
PTPRE (PREP226), FGR (PREP234), PF4 (PREP113),
CLP (PREP135), and prosaposin (PREP77) are currently
commercially available, it may be worthwhile to use
these antibodies in IFAs on ethanol-ﬁxed blood cell
samples to determine whether these antibodies have
a relationship with the ANCA-staining patterns in CSS
and whether they can help conﬁrm the diagnosis in
ANCA-negative CSS patients. Unfortunately, these
experiments will have to be performed in the future
because the CSS blood samples we obtained were
used up during RNA preparation. Moreover, as CSS
occurs only very rarely (only 2.4 patients per 1
million people in Japan), it will take some time to
accumulate enough patients for such a study.
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